Phase II Study: Bispecific Oral Drug Tops Leading JAK Inhibitor for RA

(MedPage Today) -- MILAN -- A novel oral agent that blocks two different kinase enzymes was possibly more effective against rheumatoid arthritis (RA) than the currently approved drug tofacitinib (Xeljanz) in a head-to-head study, a researcher...
Source: MedPage Today Rheumatology - Category: Rheumatology Source Type: news